Two policy disputes are testing how drugmakers and regulators handle specialized medicines. Missouri is challenging Eli Lilly’s conditions for hospital discounts, while the FDA is proposing a new approval pathway for individualized gene therapies. The issues are separate, but both turn on a practical question: how should rules adapt when a medicine, its intended use, or the information attached to its distribution doesn’t fit a simple one-size-fits-all process?
Missouri challenges Lilly’s 340B terms
Missouri Attorney General Catherine Hanaway has ordered Lilly to stop requiring hospitals to provide claims data to receive discounted medicines through the federal 340B Drug Pricing Program. In an Oct. 26 cease-and-desist letter, Hanaway said the company had “broken” its promise to sell medicines through the program to eligible Missouri hospitals. She also alleged that Lilly made “false and misleading statements” and violated state law. The warning adds to state pushback against drugmakers’ data requirements for 340B discounts.
The dispute puts a condition attached to a discount at the center of the disagreement. Lilly’s requirement, as described in the letter, links access to discounted medicines with hospitals supplying claims data. Hanaway’s position is that the condition conflicts with the company’s commitments to eligible hospitals and state law. Those are allegations in a cease-and-desist letter, not a final ruling on the merits, so the claims should be understood as the attorney general’s stated case.
That distinction matters. A dispute over the terms of a discount can involve more than the price a hospital pays: it can also raise questions about what information a supplier may demand, what hospitals must disclose, and how program participants interpret their obligations. Claims data can describe how medicines are used and billed. A data requirement may therefore be viewed by a company as part of managing distribution, while hospitals or public officials may see it as a condition that changes the practical terms of access.
The source doesn’t specify what claims data Lilly seeks, how the information would be used, or what response the company has made. Those details would help readers assess the competing positions. Without them, the clearest point is narrower: Missouri is challenging the connection between data sharing and access to 340B discounts, and the state is asserting that the arrangement violates existing commitments and law.
This is more significant than it looks. Requirements like this can shape whether eligible institutions can obtain discounted medicines on terms they consider workable. If you're working in this space, the immediate question is how the state’s allegations will be addressed and whether similar objections will arise elsewhere. The broader tension is plain: participants may agree that a discount is available while disagreeing about the conditions attached to it.
FDA proposes a pathway for tailored gene therapies
The FDA has issued draft guidance that could simplify approval of some individualized gene therapies. The agency has generally required a separate drug application for each patient’s customized treatment, even when therapies use the same basic approach to target different genes. Rare disease advocates say that process creates an unaffordable regulatory burden.
Individualized therapies pose a challenge for approval systems built around medicines intended for larger groups of patients. A treatment designed around one patient’s genetic target may differ from another treatment in the target itself, even if both use a shared underlying method. Requiring a separate application for every customized version can mean repeating work across therapies that have important features in common. That’s the burden advocates are pointing to.
The draft guidance formalizes a “plausible mechanism pathway” and sets out more specific rules for licensing and updating gene editing treatments. Its practical effect will depend on how the FDA applies the proposed framework, but the approach could reduce repeated submissions for therapies built on a shared method.
The proposal appears to address a particular regulatory problem: how to evaluate a treatment when the approach is shared but the genetic target is individualized. A pathway based on a plausible mechanism could give the agency a way to consider that common foundation, while still setting expectations for the specific therapy. The details will matter. The source doesn’t describe the proposed evidence standards or explain how the FDA would decide when two treatments qualify as sufficiently similar under the framework.
And this is the part most people overlook: simplifying the application process doesn’t, by itself, establish that a therapy works or that every version can be assessed in the same way. The draft’s value will depend on how clearly it explains what evidence is needed and how updates to gene editing treatments should be handled. A shared method may reduce duplication, but the agency still has to judge the treatment being proposed.
What the disputes signal
The two developments concern different institutions and different kinds of medicine, yet each exposes a strain in the rules surrounding specialized care. In Missouri, the argument is over whether hospitals must supply data to obtain discounted medicines. At the FDA, the question is whether a common therapeutic method can support a more efficient approval route for treatments tailored to individual patients.
Neither development settles the underlying dispute. Missouri’s letter states the attorney general’s allegations; it doesn’t establish the final outcome. The FDA’s document is draft guidance, and its practical reach will depend on the final framework and how the agency applies it. That said, both cases show why the details of implementation matter as much as the broad policy goal.
For hospitals and rare disease advocates, the consequences will turn on terms that are still contested or under development. A discount can be less useful if the conditions for receiving it are disputed, and a new approval pathway can fall short if its requirements remain too difficult to meet. The direction is clear, but the results aren’t.